🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are increasing worldwide, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Data and Global Access

According to data published in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The trial enrolled hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to register and commercialise the drug in numerous developing nations.

Medical professionals directly involved have shared positive views. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.